EG24168A - N-[5-iii5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases - Google Patents

N-[5-iii5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases

Info

Publication number
EG24168A
EG24168A EG20001523A EG20001523A EG24168A EG 24168 A EG24168 A EG 24168A EG 20001523 A EG20001523 A EG 20001523A EG 20001523 A EG20001523 A EG 20001523A EG 24168 A EG24168 A EG 24168A
Authority
EG
Egypt
Prior art keywords
iii5
oxazolyl
thiazolyl
thio
alkyl
Prior art date
Application number
EG20001523A
Other languages
English (en)
Inventor
Raj N Misra
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/464,511 external-priority patent/US6262096B1/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of EG24168A publication Critical patent/EG24168A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EG20001523A 1999-12-15 2000-12-09 N-[5-iii5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases EG24168A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/464,511 US6262096B1 (en) 1997-11-12 1999-12-15 Aminothiazole inhibitors of cyclin dependent kinases
US61662700A 2000-07-26 2000-07-26

Publications (1)

Publication Number Publication Date
EG24168A true EG24168A (en) 2008-09-10

Family

ID=27041008

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20001523A EG24168A (en) 1999-12-15 2000-12-09 N-[5-iii5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases

Country Status (29)

Country Link
EP (1) EP1240166B1 (de)
JP (1) JP2003516987A (de)
KR (1) KR100738132B1 (de)
CN (1) CN1433416A (de)
AR (1) AR026974A1 (de)
AT (1) ATE289306T1 (de)
AU (1) AU783719B2 (de)
BR (1) BR0016424A (de)
CA (1) CA2394552A1 (de)
CO (1) CO5261565A1 (de)
CZ (1) CZ20022015A3 (de)
DE (1) DE60018205T2 (de)
DK (1) DK1240166T3 (de)
EG (1) EG24168A (de)
ES (1) ES2236034T3 (de)
HK (1) HK1049661B (de)
HU (1) HUP0301032A3 (de)
IL (2) IL149755A0 (de)
MX (1) MXPA02005870A (de)
MY (1) MY125768A (de)
NO (1) NO323726B1 (de)
NZ (1) NZ519120A (de)
PE (1) PE20011026A1 (de)
PL (1) PL364921A1 (de)
PT (1) PT1240166E (de)
RU (1) RU2002119016A (de)
TW (1) TWI273103B (de)
UY (1) UY26481A1 (de)
WO (1) WO2001044242A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6414156B2 (en) 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
CA2417254A1 (en) * 2000-07-26 2002-02-07 Bristol Myers Squibb Company N-¢5-¢¢¢5-alkyl-2-oxazolyl!methyl!thio!-2-thiazolyl! carboxamide inhibitors of cyclin dependent kinases
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP4105948B2 (ja) 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
KR100909665B1 (ko) 2000-12-21 2009-07-29 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물
NZ538426A (en) 2002-08-02 2007-05-31 Vertex Pharma Pyrazole compositions useful as inhibitors of glycogen synthase kinase-3 (GSK-3)
US7392929B1 (en) 2004-07-26 2008-07-01 Zephyros, Inc. Weldable synthetic material
JP5475235B2 (ja) 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
DE102005008310A1 (de) * 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US8236128B2 (en) 2006-10-26 2012-08-07 Zephyros, Inc. Adhesive materials, adhesive parts formed therewith and their uses
US20110294782A1 (en) * 2006-11-10 2011-12-01 Massachusetts Institute Of Technology Small molecule pak inhibitors
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases

Also Published As

Publication number Publication date
BR0016424A (pt) 2002-08-20
NO20022817L (no) 2002-08-14
WO2001044242A9 (en) 2001-11-08
NZ519120A (en) 2004-03-26
CZ20022015A3 (cs) 2003-02-12
MXPA02005870A (es) 2003-01-28
WO2001044242A1 (en) 2001-06-21
IL149755A (en) 2009-09-22
RU2002119016A (ru) 2004-01-10
AR026974A1 (es) 2003-03-05
NO20022817D0 (no) 2002-06-13
PE20011026A1 (es) 2001-12-02
AU2726401A (en) 2001-06-25
EP1240166A1 (de) 2002-09-18
HK1049661B (zh) 2005-10-07
HUP0301032A2 (hu) 2003-08-28
KR100738132B1 (ko) 2007-07-10
CA2394552A1 (en) 2001-06-21
CN1433416A (zh) 2003-07-30
NO323726B1 (no) 2007-07-02
UY26481A1 (es) 2001-07-31
PT1240166E (pt) 2005-07-29
DE60018205D1 (en) 2005-03-24
DK1240166T3 (da) 2005-06-20
CO5261565A1 (es) 2003-03-31
HUP0301032A3 (en) 2009-03-30
ES2236034T3 (es) 2005-07-16
JP2003516987A (ja) 2003-05-20
ATE289306T1 (de) 2005-03-15
HK1049661A1 (en) 2003-05-23
EP1240166B1 (de) 2005-02-16
AU783719B2 (en) 2005-12-01
DE60018205T2 (de) 2006-02-16
KR20020067546A (ko) 2002-08-22
PL364921A1 (en) 2004-12-27
MY125768A (en) 2006-08-30
TWI273103B (en) 2007-02-11
IL149755A0 (en) 2002-12-01

Similar Documents

Publication Publication Date Title
HK1049662A1 (zh) 細胞周期蛋白依賴激酶氨基噻唑抑制劑
EG24168A (en) N-[5-iii5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
HUP0300974A3 (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases, pharmaceutical compositions containing them and their use
EG24028A (en) Aminothiazole inhibitors of cyclin dependent kinases
EG24409A (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases
EP1087951A4 (de) Durch kohlenstoff substituierte aminothiazole als inhibitoren von zyclin-abhägigen kinasen
LT2000033A (en) 4-aminothiazole derivatives as inhibitors of cyclin-dependent kinases
EG24027A (en) Pyrrolotriazine inhibitors of kinases
PL350001A1 (en) Purine inhibitors of cyclin dependent kinase 2 and iκ-aα
PL352282A1 (en) Derivatives of thiazoles and pharmaceutical compositions containing these derivatives
AP2001002298A0 (en) Inhibitors of impdh enzyme
AU6111000A (en) Inhibitors of viral helcase
GB9809869D0 (en) Inhibition of protein kinases
AU5619400A (en) Statine-derived tetrapeptide inhibitors of beta-secretase
HUP0001699A2 (en) Arrangement for decanting of blood
AU141671S (en) Set of containers
AU2001229727A1 (en) 3-aminopyrazole inhibitors of cyclin dependent kinases
AU3636201A (en) Antisense modulation of protein kinase c-theta expression
AU7788500A (en) Use of substance p antagonists for influencing the circadian timing system
NO20012832D0 (no) Heterocykliske karboksamid-holdige tiourea-inhibitorer for herpesvirus inneholdende fenylendiamingruppe
NO20012838L (no) Tiourea-inhibitorer for herpesvirus
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
NO20012837D0 (no) Tiourea-inhibitorer for herpesvirus
AU4021700A (en) Methods of use of beta1-integrin inhibitors
HK1029109A1 (en) Aminothiazole inhibitors of cyclin dependent kinases